Purpose: To report one-year real-world evidence on intraocular inflammation (IOI) adverse events (AEs) in patients undergoing faricimab therapy in a tertiary care hospital.
Methods: A retrospective review of electronic medical records was conducted for patients receiving faricimab treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) at Moorfields Eye Hospital between September 1st, 2022, and August 31st, 2023. The primary outcome was the incidence of IOI (excluding endophthalmitis).
Results: 2 318 eyes from 1 860 patients were included and underwent a total of 10 297 injections. A total of 20 eyes (16 patients) had ≥ 1 adverse event of IOI. Estimated incidence of IOI was 0.19% per injection (95%CI 0.12-0.30), 0.86% per eye (95% CI 0.53- 1.33] and 0.86% per patient (95%CI 0.49- 1.39). IOI mostly occurred within the first injections (median 3.5 injections, range 1-10). All cases presented with anterior uveitis and were associated with vitritis in 4 eyes (20%). No cases of posterior uveitis or evidence of retinal vascular occlusion were reported. There was no statistically significant difference between mean visual acuity before and after IOI event (0.40 logMAR and 0.378 logMAR respectively, p = .26).
Conclusion: In this real-world report, faricimab was well tolerated with an incidence of IOI-related AEs consistent to that observed in registration trials. The AEs were generally mild and had a favourable prognosis.